0.46
+0.0505(+12.32%)
Currency In USD
Address
61 Wilton Road
Westport, CT 06880
United States of America
Phone
203 221 7381
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
June 30, 2023
| Name | Title | Pay | Year Born |
| Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, Chief Executive Officer & Chairman of the Board | 597,007 | 1959 |
| Mr. James M. Ahlers | Executive Vice President of Corporate Finance | 75,088 | 1964 |
| Mr. John Wesolowski CPA, M.B.A. | Principal Accounting Officer & Controller | 260,898 | 1960 |
| Mr. Joseph Talamo CPA, M.B.A. | Chief Financial Officer | 416,930 | 1969 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.